DE10139783C1 - Zellzusammensetzungen zur Behandlung von Osteoarthrose, sowie Verfahren zu deren Herstellung - Google Patents
Zellzusammensetzungen zur Behandlung von Osteoarthrose, sowie Verfahren zu deren HerstellungInfo
- Publication number
- DE10139783C1 DE10139783C1 DE10139783A DE10139783A DE10139783C1 DE 10139783 C1 DE10139783 C1 DE 10139783C1 DE 10139783 A DE10139783 A DE 10139783A DE 10139783 A DE10139783 A DE 10139783A DE 10139783 C1 DE10139783 C1 DE 10139783C1
- Authority
- DE
- Germany
- Prior art keywords
- cells
- cell composition
- mesenchymal
- cell
- joint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 87
- 238000000034 method Methods 0.000 title claims abstract description 63
- 238000011282 treatment Methods 0.000 title claims abstract description 31
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 17
- 201000008482 osteoarthritis Diseases 0.000 title abstract description 10
- 210000004027 cell Anatomy 0.000 claims abstract description 237
- 210000001179 synovial fluid Anatomy 0.000 claims abstract description 64
- 230000007547 defect Effects 0.000 claims abstract description 30
- 210000001519 tissue Anatomy 0.000 claims abstract description 23
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 21
- 210000000845 cartilage Anatomy 0.000 claims abstract description 20
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 18
- 238000004113 cell culture Methods 0.000 claims description 11
- 210000000130 stem cell Anatomy 0.000 claims description 11
- 210000001185 bone marrow Anatomy 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 230000004069 differentiation Effects 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 210000000577 adipose tissue Anatomy 0.000 claims description 6
- 210000002744 extracellular matrix Anatomy 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 239000005482 chemotactic factor Substances 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 239000003973 paint Substances 0.000 claims description 4
- 239000012876 carrier material Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 101100126889 Mus musculus Kctd11 gene Proteins 0.000 claims 1
- 101150106653 Ren1 gene Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000001575 pathological effect Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 239000002243 precursor Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 4
- 210000003321 cartilage cell Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000003412 degenerative effect Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000037231 joint health Effects 0.000 description 4
- 230000000405 serological effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000005553 drilling Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 102100031107 Disintegrin and metalloproteinase domain-containing protein 11 Human genes 0.000 description 1
- 101710121366 Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 description 1
- 101100478173 Drosophila melanogaster spen gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 238000006639 Goldberg reaction Methods 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 102100023487 Lens fiber major intrinsic protein Human genes 0.000 description 1
- 108010047660 Mitochondrial intermediate peptidase Proteins 0.000 description 1
- 101100513476 Mus musculus Spen gene Proteins 0.000 description 1
- 201000009859 Osteochondrosis Diseases 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- -1 PDGF Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 208000013201 Stress fracture Diseases 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- NQLVQOSNDJXLKG-UHFFFAOYSA-N prosulfocarb Chemical compound CCCN(CCC)C(=O)SCC1=CC=CC=C1 NQLVQOSNDJXLKG-UHFFFAOYSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1317—Chondrocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10139783A DE10139783C1 (de) | 2001-08-14 | 2001-08-14 | Zellzusammensetzungen zur Behandlung von Osteoarthrose, sowie Verfahren zu deren Herstellung |
| PCT/EP2002/009080 WO2003015803A1 (de) | 2001-08-14 | 2002-08-13 | Zellzusammensetzungen zur behandlung von osteoarthrose, sowie verfahren zu deren herstellung |
| JP2003520762A JP2005503146A (ja) | 2001-08-14 | 2002-08-13 | 変形性関節症の治療に用いるための細胞組成物と、その製造方法 |
| EP02764845A EP1418927A1 (de) | 2001-08-14 | 2002-08-13 | Zellzusammensetzungen zur behandlung von osteoarthrose, sowie verfahren zu deren herstellung |
| US10/486,956 US20040241144A1 (en) | 2001-08-14 | 2002-08-13 | Cell compositions for use in the treatment of osteo-arthrosis, and methods for producing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10139783A DE10139783C1 (de) | 2001-08-14 | 2001-08-14 | Zellzusammensetzungen zur Behandlung von Osteoarthrose, sowie Verfahren zu deren Herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10139783C1 true DE10139783C1 (de) | 2003-04-17 |
Family
ID=7695336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10139783A Expired - Fee Related DE10139783C1 (de) | 2001-08-14 | 2001-08-14 | Zellzusammensetzungen zur Behandlung von Osteoarthrose, sowie Verfahren zu deren Herstellung |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20040241144A1 (enExample) |
| EP (1) | EP1418927A1 (enExample) |
| JP (1) | JP2005503146A (enExample) |
| DE (1) | DE10139783C1 (enExample) |
| WO (1) | WO2003015803A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8734828B2 (en) | 2006-10-06 | 2014-05-27 | Biotissue Ag | Matrix-gel graft without cells |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10333901A1 (de) * | 2003-07-21 | 2005-03-10 | Transtissue Technologies Gmbh | Verwendung von Chemokinen zur Rekrutierung von humanen mesenchymalen Vorläuferzellen zur Regeneration von Gelenkdefekten |
| KR101598947B1 (ko) * | 2004-09-24 | 2016-03-08 | 메소블라스트, 아이엔씨. | 간엽 전구세포의 증식 및/또는 생존성 증강 방법 |
| DE102005030614B4 (de) * | 2005-06-30 | 2014-05-08 | Biotissue Ag | Zellfreies Transplantat, dessen Verwendung, Verfahren zu dessen Herstellung, dabei hergestellte Matrix mit Gel und Verfahren zur Herstellung dieser Matrix mit Gel |
| EP1957633B1 (en) | 2005-10-13 | 2013-12-18 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
| US9598669B2 (en) | 2005-12-29 | 2017-03-21 | Anthrogenesis Corporation | Composition for collecting placental stem cells and methods of using the composition |
| WO2007079184A2 (en) * | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
| EP2471903B1 (en) | 2005-12-29 | 2018-02-14 | Anthrogenesis Corporation | Placental stem cell populations |
| NZ571127A (en) | 2006-03-07 | 2012-01-12 | Geeta Shroff | Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation |
| US7993918B2 (en) | 2006-08-04 | 2011-08-09 | Anthrogenesis Corporation | Tumor suppression using placental stem cells |
| JP2010518812A (ja) | 2007-02-12 | 2010-06-03 | アンスロジェネシス コーポレーション | 接着性胎盤幹細胞由来の肝細胞および軟骨細胞、ならびにｃｄ３４＋、ｃｄ４５−胎盤幹細胞の濃縮細胞集団 |
| PL2120977T3 (pl) | 2007-02-12 | 2013-12-31 | Anthrogenesis Corp | Leczenie chorób zapalnych z zastosowaniem łożyskowych komórek macierzystych |
| US8263065B2 (en) | 2007-09-28 | 2012-09-11 | Anthrogenesis Corporation | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
| DK2329012T3 (da) | 2008-08-20 | 2020-08-24 | Celularity Inc | Behandling af slagtilfælde under anvendelse af isolerede placentaceller |
| EP3172963B1 (en) | 2008-08-20 | 2019-02-06 | Celularity, Inc. | Improved cell composition and methods of making the same |
| DK2331109T3 (da) | 2008-08-22 | 2013-09-08 | Anthrogenesis Corp | Fremgangsmåder og sammensætninger til behandling af knogledefekter med placentale cellepopulationer |
| RU2562154C2 (ru) | 2008-11-19 | 2015-09-10 | Антродженезис Корпорейшн | Амниотические адгезивные клетки |
| KR20120115602A (ko) | 2010-01-26 | 2012-10-18 | 안트로제네시스 코포레이션 | 태반 줄기 세포를 사용한 골 관련 암의 치료 |
| PT2556145T (pt) | 2010-04-07 | 2016-10-25 | Anthrogenesis Corp | Angiogénese usando células estaminais placentárias |
| EP2555783A1 (en) | 2010-04-08 | 2013-02-13 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
| KR20230096132A (ko) | 2010-07-13 | 2023-06-29 | 셀룰래리티 인코포레이티드 | 천연 킬러 세포의 생성 방법 |
| US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
| US9040035B2 (en) | 2011-06-01 | 2015-05-26 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
| AU2012323963B2 (en) * | 2011-10-13 | 2017-10-12 | Solventum Intellectual Properties Company | Stimulation of cartilage repair using reduced pressure treatment |
| CN103961373A (zh) * | 2013-02-04 | 2014-08-06 | 西比曼生物科技（上海）有限公司 | 异体间质血管层细胞和异体间充质祖细胞在预防或治疗骨性关节炎中的应用 |
| JP2016506968A (ja) | 2013-02-05 | 2016-03-07 | アントフロゲネシス コーポレーション | 胎盤由来のナチュラルキラー細胞 |
| US20210047621A1 (en) | 2018-03-12 | 2021-02-18 | Universidade Do Porto | Compositions for use in the treatment of musculoskeletal conditions and methods for producing the same leveraging the synergistic activity of two different types of mesenchymal stromal/stem cells |
| CN108815187A (zh) * | 2018-07-20 | 2018-11-16 | 深圳市第二人民医院 | 一种包含人关节液外泌体的制剂及其使用方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486359A (en) * | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2288690A1 (en) * | 1997-05-13 | 1998-11-19 | Osiris Therapeutics, Inc. | Osteoarthritis cartilage regeneration using human mesenchymal stem cells |
| US6835377B2 (en) * | 1998-05-13 | 2004-12-28 | Osiris Therapeutics, Inc. | Osteoarthritis cartilage regeneration |
| DE60143517D1 (de) * | 2000-04-25 | 2011-01-05 | Osiris Therapeutics Inc | Wiederherstellung der gelenken mit mesenchymalen stammzellen |
| US6800298B1 (en) * | 2000-05-11 | 2004-10-05 | Clemson University | Biological lubricant composition and method of applying lubricant composition |
-
2001
- 2001-08-14 DE DE10139783A patent/DE10139783C1/de not_active Expired - Fee Related
-
2002
- 2002-08-13 WO PCT/EP2002/009080 patent/WO2003015803A1/de not_active Ceased
- 2002-08-13 US US10/486,956 patent/US20040241144A1/en not_active Abandoned
- 2002-08-13 EP EP02764845A patent/EP1418927A1/de not_active Withdrawn
- 2002-08-13 JP JP2003520762A patent/JP2005503146A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486359A (en) * | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8734828B2 (en) | 2006-10-06 | 2014-05-27 | Biotissue Ag | Matrix-gel graft without cells |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003015803A1 (de) | 2003-02-27 |
| EP1418927A1 (de) | 2004-05-19 |
| JP2005503146A (ja) | 2005-02-03 |
| US20040241144A1 (en) | 2004-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE10139783C1 (de) | Zellzusammensetzungen zur Behandlung von Osteoarthrose, sowie Verfahren zu deren Herstellung | |
| DE10013223C2 (de) | Verfahren zur in vitro-Herstellung von dreidimensionalem, vitalem Knorpel- oder Knochengewebe und dessen Verwendung als Transplantationsmaterial | |
| DE69935786T2 (de) | Geführte entwicklung und unterstützung von hydrogelzellzusammensetzungen | |
| EP1242129B1 (de) | Biologisches gelenkkonstrukt | |
| DE69831957T2 (de) | Herzmuskelregenerierung unter verwendung mesenchymaler stammzellen | |
| WO1997015655A2 (de) | Neue künstliche gewebe, verfahren zu ihrer herstellung und ihre verwendung | |
| EP1792980B1 (de) | Kollagenbiomatrix und Verfahren zu ihrer Herstellung | |
| DE60016288T2 (de) | Isolierung von vorläuferzellen und deren verwendung zum wiederaufbau von bindegewebe | |
| EP2273997B1 (de) | Verfahren und zusammensetzung zur regeneration von gewebe mit hilfe von stamm- oder knochenmarkzellen | |
| DE60017757T2 (de) | Humanisierte biomaterialien enthaltend monozyten oder makrophagen, ein verfahren zu ihrer herstellung und ihre anwendungen | |
| DE69531712T2 (de) | Hybridgel, das eine biologisch aktive Substanz sekretiert | |
| US20110177170A1 (en) | implantable neuroendoprosthetic system, a method of production thereof and a method of reconstructive neurosurgical operation | |
| EP1706157B1 (de) | Verfahren zur herstellung von bandscheibenzelltransplantaten und deren anwendung als transplantationsmaterial | |
| EP1481055A1 (de) | Verfahren zur behandlung von erkranktem, degeneriertem oder geschädigtem gewebe unter verwendung von in vitro hergestelltem dreidimensionalem gewebe in kombination mit gewebezellen und/oder exogenen faktoren | |
| EP2888348B1 (de) | Zellselektionsverfahren und daraus gewonnene zellen | |
| DE102007005946A1 (de) | Therapeutische Zusammensetzung und Verwendung einer zellfreien Substanz | |
| DE19540487A1 (de) | Zellinteraktionssystem zur Induktion künstlicher Gewebe | |
| WO2022034058A1 (de) | Autologe prävaskularisierte 3d-druckverfahren-erzeugte brustgewebe-konstrukte und verfahren zu deren herstellung | |
| KR102819184B1 (ko) | 하이드로겔 및 줄기세포 스페로이드를 포함하는 골 재생용 조성물 및 이의 용도 | |
| DE102004043449B4 (de) | Verfahren zur Herstellung von Bandscheibenzelltransplantaten und deren Anwendung als Transplantationsmaterial | |
| DE102009053519B4 (de) | Verfahren zur Gewinnung von Myofibroblasten zur Herstellung von zur Transplantation geeignetem Gewebe | |
| US9750848B2 (en) | Method of preparing an implantable neuroendoprosthetic system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8100 | Publication of the examined application without publication of unexamined application | ||
| 8304 | Grant after examination procedure | ||
| 8364 | No opposition during term of opposition | ||
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee | ||
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |
Effective date: 20150303 |